Platinum-Resistant Malignant Female Reproductive System Neoplasm

Platinum-Resistant Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

112 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 58
Recruiting: 30
Ph III recruiting: 3
Growth YoY: —
Industry share: 47%
Top sponsor: National Cancer Institute (NCI)
Termination share: 53.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (25)

clinicaltrialsPublishedShowing 1–50 of 56 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07265739	Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer	not yet recruiting	Phase 2	27	Massachusetts General HospitalOTHER	1	Sep 22, 2026	clinicaltrials
NCT05081609	A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies(IL Believe)	active not recruiting	Phase 1 / Phase 2	320	Ascendis Pharma Oncology Division A/S